Introduction
The recent explosion of genetic and pharmacogenetic studies increased the available knowledge about heritability and genetic transmission of many diseases, in the fields of oncology, medicine, neurology and they have also contributed to augment the comprehension of some pathophysiological mechanisms of the diseases with a genetic component. In fact, biomedical research is trying to define the molecular mechanisms of pharmacological effects, and to individuate operatively important polymorphisms in genes involved.
Concerning the field of psychiatry, the variation in individual response to psychotropic drugs is a crucial problem in mental health. In fact a large quote of patients continues experiencing significant psychiatric symptoms, even during and after drug treatment, and some of them develop also druginduced serious adverse events. Noteworthy, psychotropic drug efficacy may not occur until a certain time after initiation of drug treatment and this could result in a delay between the beginning of the treatment and the use of an effective drug. During this period, patients are exposed to a severe worsening of their quality of life.
The 'pharmacogenetics of mental diseases' is aimed to the search for informative correlates of psychotropic drug response in the individual genetic profile. Therefore, pharmacogenetic approaches provide both a new opportunity to identify biological predictors of psychotropic drug response and a way to determine the actual molecular substrates of psychotropic drug efficacy. 1 In the recent years a lot of pharmacogenetic and pharmacogenomic researches in psychiatric disorders, especially in schizophrenia and mood disorders, were performed. Some considerable results were obtained (for a review, See Malhotra et al., 1 Serretti and Artioli, 2 Arranz et al., 3 Kawanishi et al. 4 and Waterwort et al. 5 ). Nevertheless, ethical issues related to the use of genotyping are not yet commonly debated, especially according to psychiatry. Does genetics pose any specific ethical problem? In somebody's opinion genetic knowledge is far more dangerous than other fields of science. This is mainly due to misuse of genetics in recent years by Nazi regimen and other similar social organizations. 6 Genetics is particularly linked to the concept of race that caused many distortions. Even if this misconcept has been clearly confuted 7 large sections of the public opinion are linked to it.
Similarly, psychiatry is often seen by the general population, as well as by a large part of scientists, as an unclear and potentially dangerous field of science. Even if this misconcept also has been faced by recent development toward operationalized assessment 8 and standardized intervention guidelines, 9, 10 we are still far from having psychiatry completely accepted within standard medical sciences.
In our opinion, progress in every fields of science and technology, and even changes in cultural tendencies could influence how the human beings will be like and behave in the future, and this characteristic is not a peculiarity of genetics or psychiatry itself.
However, more in detail, which are the aspects that are believed more problematic by experts, specifically in the psychiatric field? A recently published paper investigating the most common issues raised from 211 UK local research ethics committees on psychiatric research reported that the most problematical areas were informed consent (60%) and confidentiality (16%). The use of placebos (and washout periods) (17%), the validity of psychiatric questionnaires (15%) and overuse of psychiatric 'jargon' (13%) also raised concern. 11 Undoubtedly, the same problematic issues of psychiatric pharmacology research on the whole can be applied to the field of psychiatric pharmacogenetics: the difference is that the clinical impact of genetic studies is smaller, essentially for the probabilistic nature of the genetic information, mostly in psychiatry. We should never forget that genetic data gives information about the initial input we received from parents, and that a large number of environmental modulating events followed for the final outcome.
The system of ethical rules that evolved over the past 30 years has been built for the need to ensure respect for research subjects and to protect them from exploitation and unwarranted harm: the field of pharmacogenetic studies, however, generates problematic issues which were only recently faced. The Nuffield council stated some rules and ethical principles, 12 and recently published papers debated some ethical issues in psychiatric genetics. [13] [14] [15] [16] The most debated topics regard informed consent, confidentiality and the storage of human DNA. This article will focus on ethical issues of pharmacogenetic research on mental illness.
Informed consent
Informed consent represents an essential condition in pharmacogenetics as well as in all other research investigations. The Nuremberg Code, made with the intent of preventing the outright abuse suffered by human research subjects during the years preceding the World War II, 6 defines informed consent as the first of a list of essential requisites for an ethically acceptable research. The capacity of the subject to take part to the process of informed decision making is a critical component. The question is crucial in the case of subjects affected by mental disorders. Decision-making capacity is a main issue. When decisional impairment or incapacity prevents the individual to reach this purpose, other important considerations arise.
The term 'decisional impairment' refers to a limitation or incapacity that is not part of normal growth and development. In practice, it is not usually difficult to determine whether a subject lacks all decision-making ability, so opinions of incapacity in this sense are not often a matter of disagreement. Much more challenging is determining whether someone with limited decisional capacity has sufficient capacity to make a particular choice.
Decision-making ability is partly determined by the chosen standard of competence. [17] [18] [19] Capacity refers to a situation-or context-specific ability. The standards for assessing decisionmaking capacity should include the ability to postulate a choice, to understand relevant information, to appreciate the situation and its consequences, and to rationally manage information. These standards were initially developed to assess the capacity to consent to treatment and not for research purposes. Recently, however, the American Psychiatric Association approved guidelines. 20 for assessing decision-making capacity in research candidates, substantially relied on the same standards.
Another component often encountered is the variable manifestation of decision-making impairments. The gradual loss of capacity rarely follows a straight line, and in psychiatric illnesses such as bipolar disorder, cycles of mania and depression sometimes follow substantial periods of normal mood.
It is neither ethically acceptable nor empirically accurate to presume that individuals with mental disorders are impaired in their ability to decide. [21] [22] [23] It is also inappropriate to suppose that those who exhibit some decisionmaking deficit cannot be helped to participate in a valid consent process. For example, depressed patients are frequently pessimistic, for their feelings of impossibility of recovering, and usually they are not favorable to treatments or to the involvement of their relatives, because of their sense of guilt, in the case of a family study or a sib-pair genetic study. Manic patients are not less suspicious towards researches, both for their certainty not to be ill and for their certainty to be exploited, or submitted to mysterious experiments. Determining the proper standards to assess capacity poses a major challenge in research involving subjects with mental disorders that may affect decision-making capacity. Persons with such disorders vary widely in their ability. They may retain such capacity, or possess it intermittently, or be permanently unable to make decisions for themselves.
If there is a consensus on the opinion that decisional capacity requires a certain level of cognitive ability, less agreement exists on whether subjects should be judged incapable if their affective perception of the choice fails. In a recent article, 24 Elliot argues how some depressed persons 'might realize that a protocol involves risks, but simply not care about the risks,' or 'as a result of their depression, may even want to take risks.' For this fact, judgments about capacity to consent to research should take into account emotional attitudes. He also proposes that subjects failing to exhibit a 'minimal degree of concern for their welfare' should be judged incapable of decision making. Other researches do not share this position, contending that such an approach could represent an excessive paternalism toward psychiatric patients, as insufficient data exist on the extent of emotional impairment among depressed individuals, also because affective impairment is difficult to assess. The matter is really more difficult when we are obliged to ask for consent to delusional patients, who may be suspicious both for the treatment and for the genetic analysis. The most common strategy is to wait to gather the informed consents until the reduction of the symptomatology. However, this could be a problem for acute phase pharmacogenetic studies, while it should be performed for longterm maintenance studies which can start during a stable phase. It is generally agreed that capacity to give consent to participation in research projects cannot be determined through a general mental status assessment. 25 Instead, investigators must develop and present a specific explanation of their project and evaluate its understanding by the candidates. Notwithstanding this discussion, some people affected by psychiatric disorders can first provide informed and voluntary consent, and then lose their capacity for independent choice. As a result, they become unable to exercise their right to withdraw from a study. Study designs should, therefore, provide for this contingency.
Obviously, the special ethical obligations of scientific investigators and institutions sponsoring or carrying out research with persons who may be impaired are self-evident. Investigators ought to take into account not only the psychological and medical factors affecting these subjects, but also the nature of the impaired decision-making. In fact, even normal individuals may become disoriented if forced by their diseases into the role of patients, with social impairment and feelings of vulnerability. Persons with a mental disorder may experience Ethics of pharmacogenetics A Serretti and P Artioli the consequences of institutionalization in a more pronounced manner. Therefore, the conditions under which an informed consent process takes place, including how information is presented and who is responsible for obtaining consent, can be critical in influencing the quality and thus the ethical validity of the consent obtained. 26 The intervention of people with similar mental disorders who have already participated in the research, or the use of written or visual aids to clarify the research details ought to be encouraged to improve this process.
The literature offers some suggestions for ensuring authentic voluntary participation. [27] [28] [29] [30] [31] [32] [33] Who should explain to the patient the purposes of research and obtain the consent to participation? The Declaration of Helsinki 34 states that 'when obtaining informed consent for the research project the physician should be particularly cautious if the subject is in a dependent relationship to him or her or may consent under duress.' In these circumstances, 'informed consent should be obtained by a physician who is not engaged in the investigation and who is completely independent of this official relationship.' Other ethic regulations show how, sometimes, it should be better for the caregiver not to be involved in the informed consent process at all, also to avoid alteration in the doctor-patient relationship. 35 Subjects should also 'comprehend the fact that the suggested intervention is made for research purposes and that they may decide against participation 'without jeopardizing the care and concern of health care providers.' In addition, the Nuremberg Code provides the descriptive characteristics of a voluntary decision, as 'free of coercion and undue influence.' Nevertheless, patients may feel indebted to the provider, giving their consent nearly as a gift for taking care of them.
It is also important to recognize that investigators face conflicting interests, and some may consciously or perhaps unconsciously, consider subjects capable to give informed consent or (at least partially) influence subjects for the purpose of an advance their research objectives.
Key points
Informed consent is the starting point of any ethically acceptable pharmacogenetic research.
Decision-making assessment is crucial for obtaining a valid informed consent.
Decision-making is generally believed to be adequate in psychiatric patients, however:
Avoiding acute phases of the illness is suggested if compatible with the study. Affective distortion of the decisionmaking process should be considered. Treating physician should avoid the risk of use his/her power in the informed consent process. People with similar mental disorders who have already participated in the research, or the use of written or visual aids to clarify the research details should be encouraged.
Storage of DNA
Pharmacogenetic studies require blood sampling to obtain DNA. The main legal and ethical issues posed by DNA storage are the identification of who and under what conditions will store samples. It is thus recommended to clarify the description and aims of the genotyping (limited to certain genes involved in pharmacological response or extended to other collateral investigations) including its purpose (main expected outcome), limitations and predictive value of possible outcomes (expected clinical utility of identified liability genes), the use of samples (which laboratory will access them), including whether samples will be used only for the purpose for which they were collected and then be destroyed or used for future analyses. If researchers believe useful that samples will be retained after the initial use, they should clearly state this in the initial consent procedure in order to avoid uncertainties that might arise in the future. 36, 37 In fact, it has been suggested that after the initial study a simple request to the local ethical committee is sufficient in order to perform further analyses, given that subjects are no more traceable due to anonimization procedures. However, this should be considered only a last chance and not a routine strategy. We suggest to consider this possibility routinely given that results from researches usually open hypothesis for future investigations that cannot be forecasted initially. Moreover, a priori knowledge about pharmacogenetic mechanisms of action is far from complete and genome screening may be involved in some studies instead of focusing on candidate genes. Finally, further uses such as DNA pooling with other samples are possible, therefore a specification on the informed consent that future investigations will be performed on the samples seems ethically adequate. A continuous contact with subjects is suggested also for the possible practical applications of results: in case a predictive factor is discovered, this information could influence the everyday subject clinical management and it should therefore communicated to the subject and the treating physician. Information about relatives is a complex issue given that relatives information is useful for the research and patient treatment but informed consent is not routinely asked to relatives who do not actively participate to the research.
It should be therefore at least clarified for the patient the scope and permission to use samples or results for relatives counseling, and if so, which relatives; it should be expressed the possibility of future refinements and the expectations that the samples will be analyzed for other studies, with communication of the results.
The following factors, among others, should be considered in deciding whether it is appropriate to use previously collected samples without contacting the individual: is the burden of contacting individuals making impracticable to conduct research? Is there any prior informed consent, and if so, what is its content? Which are the possible risks, and what are the possible benefits?
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Another issue that should be clarified is the duration of storage of genetic materials (the time limit of 15 years used for psychopharmacology studies seems adequate, also in the light of DNA degradation), including provision for future access by patients or their designee, and the option to have their samples withdrawn or destroyed at any time.
Key points
The following aspects should be reported in the consent:
Description and aims of the genotyping. Purpose of the genotyping. Limitations and predictive value of possible outcomes. The laboratory that will use samples. Specify if samples will be used also for future analyses.
A continuous contact with patients is suggested for the communication of clinically relevant information to the subject.
Counseling to relatives should be considered.
Confidentiality
Traditional genetic studies produce specific ethical, legal and social implications that are still controversial. The stigma of being 'labeled' as carriers of a disease gene has enormous consequences for family, work and personal environments. 38 Pharmacogenetics is less involved in such implications, because candidates to pharmacogenetic researches are already affected by a disease, and they are investigated for the genes involved in pharmacological response only.
However, the anonymousness of the genotyped samples for pharmacogenetic research and the resulting information should be considered strictly personal. In order to respect the individual privacy and confidentiality of genetic information, any communication to third parties is prohibited without the consent of people involved. Data should be kept strictly anonymous with no reference to the original subject in order to avoid malicious intrusions in the research database.
Confidentiality problems arise when family-based studies are performed. 39, 40 In fact, information about relatives (for example about the response to drugs of a relative also affected by a mood disorder) given by the interviewed proband who has obviously given his/her consent to participate the researches, are data about a third person, who was not given the possibility to exert is right concerning information about his/her private life. Despite the scientific value of analyzing families in pharmacogenetic trials, these studies raise serious ethical problems deriving from the dynamic and social significance of 'family'. 41 Some psychological risks may arise, and disordered family dynamics could exert interfamilial pressure to participate or to not participate the studies. The incidental information one could learn from a genetic study, such as misattributed paternity, are other difficulties for the researchers. They must decide whether to disclose it to subjects, taking into account all risks and burdens connected to disclosure and to nondisclosure as well. It is best therefore to practice preventive ethics, and anticipate to the subjects the sorts of information that may be discovered and clarify what their expectations may be about its disclosure. 42 As a general principle, all the information not regarding the study protocol ought not to be communicated, either to the subject or to the family.
Key points
Though less impacting compared to diagnostic genetic studies, pharmacogenetic data should be kept strictly confidential.
Issues not related to the protocol such as nonpaternity or data about relatives should be listed in the consent or noncommunicated to subjects.
Justice
Pharmacogenetic studies also bring some changes in the traditional relationship between the physician and the patient. The shift in the attention of the health care provider, who becomes a clinical investigator, towards the family and the community, could threat and prevent the recruitment of the patients. Some ethicists are also concerned that the attention paid to particular ethnic communities might lead to the erroneous concern of a particular predisposition of individuals belonging to these isolated ethnicities to show a certain pharmacological response or to be prone to particular adverse effects, thus creating a sort of prejudice. Some genetically isolated populations might provide important suggestions in the characterization and in the understanding of heritability and patophysiologic mechanisms of various human diseases.
Research should not be conducted on a population, even if related to migration patterns or to the evolution of a genome, unless the benefit to the population is likely to outweigh the risks. 43 It is important to protect isolates against discrimination or stigmatization, by following one of the main principles for research ethics, 'the respect of the community'.
Other question will arise as soon as pharmacogenetic techniques and improved knowledge will be able to offer a custom treatment to patients: 2 ought all subjects to be typed, choosing those who could benefit of a certain treatment before starting it, or only after the patient had shown the complete absence of response or a partial response to drugs? And how individual privacy of the patient could be respected, giving at the same time useful information about treatment to affected family members who could benefit of it? The risk is increased anxiety and changed self-concept, coupled with a potentially problematic interference in familial dynamics.
Key points
Isolates are precious for pharma cogenetic studies but risk of prejudice should be balanced with benefits.
A cost-benefit analysis for a genetic screening should be performed for assuring the best benefit for patients.
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Undoubtedly, a research should be performed only if there is some benefit for participants, and not only for scientific progress.
Under a strictly paternalistic 'protection model' 44 those who lack the capacity to give informed consent, or whose capacity is uncertain, should be excluded from participation. Such exclusion seems appropriate since the underlying principle is that it is better to protect subjects from risks of harm, even at the cost of slowing the progress of scientific investigation. In this way, however, there would be fewer opportunities to assess promising new clinical approaches. Conversely others suggest the so called 'access model': 45 a barrier to research for people with mental disorders is considered a damage, for it would prevent some people from obtaining the potential benefits that such a research might offer them, either directly as a result of participating, or indirectly for the improved knowledge of their illness and of methods for treating it.
The increasing costs of treatment of adverse drug reactions, 46 and the marked pressures and potential benefits will certainly increase the demand for the development and use of genotype-based pharmacotherapies. With the development of less expensive and more efficient methods for genotyping individuals, clinical pharmacogenomics is likely to have significant effects on the economic structure of research and development of research. 47 Benefit would grow exponentially: a gene polymorphism could exert a range of effects also on other conditions 48, 49 thus further informing the patient about his/her possible reactions. An example is the polymorphisms of the metabolizing enzymes (P450), rapid or slow metabolizers for a specific drug have the same behavior for a range of other drugs metabolized by the same enzyme.
The importance of 'pharmacoeconomic' considerations, such as the assessment of a cost-benefit policy for various treatments, drug availability, outcomes of medical care are becoming more and more important. 50 The benefits in term of development of customized drugs, and revaluation of old drugs, with serious adverse effects because of the intolerance of few people due to an unfavorable genetic profile, could allow a considerable benefit and a substantial improvement in scientific progress against mood disorders and other mental illnesses.
On the other hand, the precise identification of the ideal patient who will benefit from a certain drug will prevent pharmaceutical industries to invest in drugs potentially effective only in a minority of patients. This fact would constitute damage for their right to be cured, and therefore a sort of discrimination. Furthermore, should pharmaceutical companies genotype all patients in a trial for a new product, given that this might lead to a reduction in their potential market field? Sample sizes of those studies are sufficient for determining even minor effects (at least 500-600 subjects) and results could be of great benefit but at present such data are kept strictly confidential. Finally, we previously mentioned that the information coming from a pharmacogenetic analysis will only tell us that a specific drug has a certain probability to be effective in a given individual, but will not give us the certainness. In other words, the clinical usefulness of pharmacogenetic information depends on how much this data will change the a priori clinical knowledge, or, in statistical terms, how much is the variance explained; only explained variances of 40-60% have substantial clinical impact. Unfortunately, up to now, many liability genes explain less than 10% of the total variance, in the case of mood disorders as in many other fields of medicine, both for efficacy 2,51-55 and for side effect prediction. 56 Should we stop all our pharmacogenetic research then? Of course not, but knowledge is not a dichotomous issue, and partial information could be available at the beginning of the trial. Therefore, investigators should inform the patient that, as an example, a specific SNP has been previously associated with response and the present trial is aimed at refining such information. The information about the subject genotype should then be given only if clinically meaningful, that is, with explained variance of 40% or more.
Key points
Benefit for the patient is important but benefit for the community should be also considered, when not harming the single patient. Pharmacogenetics results will greatly benefit patients but companies may be interested in hiding market reducing results.
Conclusions
A great deal of works and books have been published about the ethics of genetic studies, including issues surrounding informed consent, DNA storage and communication of information regarding genetic features of individuals. Pharmacogenetics, especially in psychiatric disorders represents a particular challenge for the uncertain and complex nature of its mechanism of action (and thus the multifactorial aspect of response to psychiatric treatment) and the stigma surrounding mental health. The particular nature of these disorders, which give an emotional but also a cognitive impairment, raises problems concerning freedom of choice and accessibility of information, which represent the basic features for informed consent giving.
The general greater paternalism in the research environment is justified by a lot of reasons. Nevertheless, this should also leave some place for a more favorable opinion for a research made to follow the well being of the human community, instead of focusing only about the privacy of the single person. Basically, the human community is made of single individuals, who should take benefit of science advances, even if the price to pay is to give up a little bit of single individual privacy. In fact, recent views about ethical principles of research underline this new trend, by promoting the importance of research for future of psychiatric treatments.
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For the above-mentioned reason about the risk/benefit ratio of pharmacogenetic studies, however, we must underline the importance of performing ethically accurate research projects, to implement the percentage of explained variance and assure an actual clinical utility to our results. In our opinion, considering the relative low risk of being unethical, if the above-mentioned guidelines and common sense rules are respected, such studies ought to be encouraged, as they could be useful for a future improvement of caregiving.
